Navigation Links
Study Says Allergy Shots Help Children, Reduce Health Care Costs
Date:1/23/2008

BioMedEcon Study, First of its Kind in US, Finds Allergy Immunotherapy

Beneficial Even When Treatment Not Completed

MOSS BEACH, Calif., Jan. 23 /PRNewswire/ -- BioMedEcon, a leading provider of health economics and outcomes research, today announced findings of a landmark study which show allergy immunotherapy (IT) delivers important clinical benefits to children and significantly reduces health care costs, even when the appropriate course of treatment is not completed. The study of 520 low-income Florida children with allergic rhinitis found that IT was associated with significant savings across all aspects of the health care system -- inpatient, outpatient and medication treatments -- even among children who completed only a fraction of the recommended three-year treatment regimen. The study is published in the January 2008 issue of The Journal of Allergy and Clinical Immunology (JACI).

The BioMedEcon study, a first of its kind in the United States, examined nine years of data (1997-2006) on children in the Florida Medicaid program to compare health costs for the six-month period before the initiation of IT to the six-month period following IT discontinuation. Adherence to the treatment program was poor, with 39 percent of the children receiving less than six months of IT, and only 16 percent completing at least three years of IT. However, the study found that the benefits extended across children in the sample, with strikingly reduced numbers of hospitalizations, doctor's visits and prescription drugs following treatment.

"These findings are remarkable," said Cheryl S. Hankin, Ph.D., president and CSO of BioMedEcon, LLC. "Even though most of the children in our study had insufficient treatment duration, averaging less than half of the recommended course, their health care use and costs significantly declined following treatment. It is clear that allergy immunotherapy not only benefits children with allergic rhinitis, but delivers compelling cost savings to the health care system. We believe children and health care systems would benefit even more if treatment duration were sufficient."

"The research pioneered by BioMedEcon illustrates both the importance of allergy immunotherapy for children with allergies and the economic incentives for ensuring they are appropriately treated," said Robert Esch, Ph.D., Executive Vice President of Research and Development for Greer Laboratories, which sponsored the study. "These findings, which highlight the benefits for patients with allergies, their providers and insurers, will help drive and focus our efforts to provide patients easier access to treatment."

About Greer

Greer is a leading developer and provider of allergy immunotherapy products and services for treating humans and animals. Greer's highly skilled scientists provide technical support for customers by continuing to focus on improving the lives of allergic patients. Greer's clinical development programs are focused on expanding the use of immunotherapy through oral administration of allergy immunotherapy. Greer's goal is to establish the efficacy of standardized products for oral administration through clinical trials. The company was founded in 1904 and is located in Lenoir, N.C. For more information, visit http://www.greerlabs.com.

About BioMedEcon

Based in Moss Beach, California, privately-held BioMedEcon, LLC is a leading-edge provider of health economics and outcomes research. BioMedEcon applies rigorous scientific methods to create coherent, objective and practical formulary decision models, pharmaceutical and drug delivery market entry strategies, and healthcare policy recommendations. Clients and partners include established and emerging leaders in the pharmaceutical, biotech, drug delivery and medical device industries. For more information, call 650.563.9475 or visit http://biomedecon.com/. Additional study data and article reprints are available by emailing cherylhankin@biomedecon.com.


'/>"/>
SOURCE BioMedEcon, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Northwestern Memorial Transplant Program Initiates New Study
6. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
7. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):